SII, Bharat Biotech jointly pledge to work for smooth roll out of COVID-19 vaccines

Adar Poonawala, CEO, Serum Institute of India (SII) and Dr Krishna Ella, Chairman and MD, Bharat Biotech, jointly on behalf of the two companies, today communicated their combined intent to develop manufacture and supply the COVID-19 vaccines for India and globally. They said the more important task in front of them is saving the lives and livelihoods of populations in India and the world. Vaccines are a global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest.

“Now that two COVID-19 vaccines have been issued EUA (emergency use authorization) in India, the focus is on manufacturing, supply and distribution, such that populations that need it the most receive high quality, safe and efficacious vaccines. Both our companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines. Each of our companies continue their COVID-19 vaccines development activities as planned,” said the joint statement.

“Both companies respect the great work being carried out by each other and put behind us the miscommunication and misunderstanding caused during the past week. We are fully aware of the importance of vaccines for people and countries alike, we hereby communicate our joint pledge to provide global access for our COVID-19 vaccines,” said Poonawalla and Dr Ella through the statement.